Gilead Sciences Q2 Beats Street View on Robust Oncology, HIV Products…
Gilead Sciences Inc GILD reported Second quarter revenue of $6.26 billion+1% Y/Y, beating consensus of $5.86 billion, driven by increased sales of HIV and oncology
Home » HIV
Gilead Sciences Inc GILD reported Second quarter revenue of $6.26 billion+1% Y/Y, beating consensus of $5.86 billion, driven by increased sales of HIV and oncology
The new Expert Market Research report titled “United States HIV Drug Market Report and Forecast 2021-2026 provides an in-depth analysis of the United States HIV
U.S. roads have become increasingly dangerous for pedestrians, with a new analysis from Bader Law revealing a 48% increase in pedestrian fatalities since 2014. The
Losing weight can be an uphill battle for many adults, especially when traditional methods such as diet modification and increased physical activity yield slow or
In the digital world, the boundaries of ownership have become increasingly blurred. The speed at which information travels and the ease with which it can
injuredly News Provide the latest news. All News World News, Business News, Health Care, Life Style. All News Around the World Update On This Website.